Skip to content

Study · Randomized controlled trial · n = 18 · 2006

4 results

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R

The journal of sexual medicine1 Jul 2006Cited by 65 (Europe PMC)

PMID16839319 (opens in a new tab)DOI10.1111/j.1743-6109.2006.00268.x (opens in a new tab)PepBankPUB-16839319
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with sexual arousal disorder, more women reported moderate or high sexual desire after bremelanotide than after placebo.

    In plain wordsIn premenopausal women with sexual arousal disorder, more women reported moderate or high sexual desire after bremelanotide than after placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseModerate or high sexual desire
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    20 mg · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    More women reported moderate or high sexual desire following bremelanotide treatment vs. placebo (P = 0.0114)
    1 context sentence
    Summary · context
    Eighteen premenopausal women with a primary diagnosis of female sexual arousal disorder were randomly assigned to receive a single intranasal dose of 20 mg bremelanotide or matching placebo in a double-blind manner during the first in-clinic treatment session, and the alternate medication during the…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with sexual arousal disorder, positive responses about genital arousal showed a trend toward more with bremelanotide than placebo, not significant.

    In plain wordsIn women with sexual arousal disorder, feelings of genital arousal tended to be more positive after bremelanotide than placebo, but not significantly.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeFeelings of genital arousal
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    20 mg · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    a trend toward more positive responses regarding feelings of genital arousal occurred after bremelanotide compared with placebo (P = 0.0833).
    1 context sentence
    Summary · context
    Eighteen premenopausal women with a primary diagnosis of female sexual arousal disorder were randomly assigned to receive a single intranasal dose of 20 mg bremelanotide or matching placebo in a double-blind manner during the first in-clinic treatment session, and the alternate medication during the…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with sexual arousal disorder, vaginal vasocongestion during erotic videos did not change significantly with bremelanotide compared with placebo.

    In plain wordsIn women with sexual arousal disorder, bremelanotide did not significantly change vaginal blood flow during erotic videos compared with placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeVaginal vasocongestion during erotic video
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    20 mg · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Vaginal vasocongestion did not change significantly while viewing erotic videos following bremelanotide administration compared with placebo.
    1 context sentence
    Summary · context
    Eighteen premenopausal women with a primary diagnosis of female sexual arousal disorder were randomly assigned to receive a single intranasal dose of 20 mg bremelanotide or matching placebo in a double-blind manner during the first in-clinic treatment session, and the alternate medication during the…
  4. 04HumanRandomized controlled trialEfficacy outcome

    Among women who attempted intercourse within 24 hours, more were satisfied with their sexual arousal after bremelanotide than after placebo.

    In plain wordsAmong women who tried intercourse within 24 hours, more were satisfied with their arousal after bremelanotide than after placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseSatisfaction with arousal during intercourse attempts
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    20 mg · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Among women who attempted sexual intercourse within 24 hours after treatment, significantly more were satisfied with their level of sexual arousal following bremelanotide, compared with placebo (P = 0.0256).
    1 context sentence
    Summary · context
    Eighteen premenopausal women with a primary diagnosis of female sexual arousal disorder were randomly assigned to receive a single intranasal dose of 20 mg bremelanotide or matching placebo in a double-blind manner during the first in-clinic treatment session, and the alternate medication during the…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.